Pharnext (FR:ALPHA) has released an update.
Pharnext, a biopharmaceutical company focused on neurodegenerative diseases, has received an extension for its conciliation procedure until July 15, 2024, which will support its ongoing operations and the awaited Phase III clinical study results for its drug candidate PXT3003 in China. The company also reported strong support from shareholders during its recent General Meeting, with all resolutions passed by a wide margin. However, they caution investors of potential share price volatility and capital loss due to dilutive financing operations.
For further insights into FR:ALPHA stock, check out TipRanks’ Stock Analysis page.
